SC Labs Expands Cannabis and Hemp Testing Services with C4 Laboratories Acquisition
LOS ANGELES– SC Labs, a leading cannabis and hemp testing company in the U.S., announced today its acquisition of C4 Laboratories, a Scottsdale-based lab offering advanced testing capabilities to ensure quality and accuracy. With the addition of C4 Labs, SC Labs is now licensed and accredited in five states, including Arizona, California, Colorado, Michigan, and Oregon.
The acquisition aligns with SC Labs’ commitment to science-driven consumer safety and operational excellence, and it will allow the company to provide brands with a seamless testing and data management process. As combined medical and recreational cannabis sales in the U.S. are estimated to be upwards of $52.6 billion by 2026, consumers are increasingly demanding confidence in the products they consume. The acquisition of C4 Laboratories and a new safety and ethics program in collaboration with ACT Laboratories and Trustintesting.org will help ensure that products are contaminant-free and accurately labeled for consumers.
“We’re thrilled to welcome the C4 team to the SC Labs family,” said Jeff Journey, CEO of SC Labs. “C4 has a demonstrated track record of scientific expertise and business acumen that fits perfectly within our values shared across locations. With this acquisition, we can continue to expand best-in-market cannabis testing services and the opportunity to service multi-state growers and manufacturers.”
As part of the acquisition, all C4 Lab employees will join the SC Labs team, and the two companies will leverage top scientists with specialized cannabis testing knowledge to harmonize R&D efforts, improve the data experience, and push for positive regulatory change. The potential for growth is limitless, according to Ryan Treacy, CEO and Founder of C4 Labs.
SC Labs’ cannabis testing labs are located in California (Los Angeles and Santa Cruz), Michigan, Oregon, and Arizona, and the company also operates separate hemp and cannabis labs in Colorado.
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...